FMC Corporation

source: coverage-next-full ticker: FMC step: "01" title: Business Overview — FMC Corporation created: 2026-05-29

Step 01: Business Overview — FMC Corporation

Company Description

FMC Corporation is a pure-play agricultural sciences company providing crop protection products — insecticides, herbicides, fungicides, and biologicals — to farmers globally. The company's mission is to drive innovation in sustainable agriculture. As of FY2023, FMC generated approximately $4.2 billion in revenue from ~130 countries.

FMC is structured as a single reportable segment (Agricultural Sciences). The company differentiates itself through proprietary chemistry, formulation technology, and a global commercial infrastructure serving both large-scale commodity growers and specialty/high-value crop producers.

Product Portfolio by Category

Insecticides (~50% of Revenue)

FMC's insecticide franchise is anchored by diamide chemistry — specifically Rynaxypyr (chlorantraniliprole, or CTPR) and Cyazypyr (cyantraniliprole). Diamides operate through a novel mode of action (ryanodine receptor modulators), making them highly effective, low-mammalian-toxicity, and initially without resistance.

• Rynaxypyr (Chlorantraniliprole): Registered globally under trade names Coragen, Altacor, DuPont Rynaxypyr. Was FMC's single largest product — estimated ~$1.5–1.8B revenue at peak (FY2021–2022). Patent protection in major markets expired 2022–2023; Chinese generic manufacturers (Shenyang Shenhe, etc.) have entered aggressively.
• Cyazypyr (Cyantraniliprole): Second-generation diamide with broader spectrum and soil activity. Trade names include Benevia, Exirel. Currently in growth phase; patent runway extends to mid-2030s in most markets.
• Other insecticides: Radiant (spinetoram), Belt (flubendiamide — licensed), Elevest, Authority Edge combinations.

Herbicides (~30% of Revenue)

• Authority herbicide family (sulfentrazone-based): Primarily soybeans in North America; Authority Maxx, Authority First, Authority Assist.
• Isoflex (bicyclopyrone): Next-generation herbicide in corn; novel active ingredient with differentiated spectrum. Commercial launch in 2023; represents a potential $400–600M peak sales opportunity over 5–7 years.
• Established generics and combinations across global markets.

Fungicides (~15% of Revenue)

• Xyway (flutriafol): Soil-applied fungicide for corn. Unique positioning vs. foliar fungicides; targets soybean sudden death syndrome and corn diseases through in-furrow application. Limited near-term sales but long-term pipeline opportunity.
• Onsuva, Lucento: Newer fungicide launches in Europe and Latin America.
• Broad portfolio of fungicide products across specialty crops.

Biologicals & Plant Health (~5% of Revenue, fastest-growing)

• Accrue Biosciences acquisition (2022): Added bioinsecticide and plant health capabilities.
• Products leveraging natural microorganisms, plant extracts, and bio-stimulants.
• Regulatory tailwind: Biologicals face lower registration burdens; growing farmer demand for sustainability credentials.
• Expected to grow to $400–500M by 2027 per company targets.

Geographic Revenue Mix

Latin America is strategically critical — Brazil in particular is FMC's fastest-growing major market and largest single-country contributor. Brazil's complex distribution and channel dynamics (grão credit, extended terms) create both opportunity and working capital risk.

Diamide Patent Expiry Dynamics — The Central Issue

Rynaxypyr/chlorantraniliprole was co-developed with DuPont (FMC acquired the FMC rights in the 2017 asset swap; DuPont retained rights in certain markets before becoming Corteva). FMC held the global rights to CTPR in most markets.

Patent expiry timeline:

• US, Europe: Composition-of-matter patent expired ~2022
• Brazil: Key patents expired ~2022–2023
• China: Local generic manufacturers had de-facto manufacturing capability regardless of patent

Generic entry impact: Chinese manufacturers (several, including state-linked) began exporting bulk CTPR active ingredient at ~50–70% price discounts. This has pressured FMC's diamide pricing globally, particularly in Asia and parts of Latin America. FMC's response has been to emphasize formulation advantages, data package differentiation, distributor relationships, and the Cyazypyr (second-gen diamide) transition.

FMC estimates it can retain ~50–60% of the chlorantraniliprole market share (vs. generics) through brand loyalty and formulation quality, but at lower margins. The transition from Rynaxypyr dominance to a broader portfolio is the defining strategic challenge of 2023–2027.

Customer & Channel Overview

FMC sells through a two-step distribution model in most markets:

1. Distributors / Cooperatives: Large ag distributors (Nutrien Ag Solutions, Winfield United, Helena, Nufarm, independent co-ops in LatAm)
2. Retailers / Agronomists: Point of sale to end farmers

This creates a channel inventory problem: when farmer demand softens or distributors over-order, the channel absorbs excess product, leading to destocking cycles that hit manufacturers first. The 2023–2024 destocking was severe — distributors worked down ~6–12 months of excess inventory before returning to normal ordering patterns.

Competitive Position Summary

FMC is a Tier 2 global crop protection company — significant scale, proprietary IP, but notably smaller than the "Big 4" (Syngenta, Bayer Crop Science, BASF, Corteva). Its competitive advantages are:

• Diamide chemistry IP (diminishing as CTPR generifies but Cyazypyr has runway)
• Deep LatAm commercial presence
• Formulation expertise and regulatory data packages
• Speed of new product launches vs. larger/slower competitors

The diamide franchise built exceptional economics (EBITDA margins >25% at peak). The core question is whether FMC can sustain Narrow Moat economics as its flagship product faces generic competition while building the next innovation S-curve.

source: coverage-next-full ticker: FMC step: "04" title: Financial Snapshot — 3-Year P&L Analysis created: 2026-05-29

Step 04: Financial Snapshot — 3-Year P&L Analysis

Income Statement Summary

Note: All figures are approximate based on reported/adjusted financials. FMC uses "adjusted" metrics excluding amortization of acquisition intangibles (~$200M/year), restructuring, and discontinued operations.

Revenue Decline Analysis — FY2022 to FY2023 Bridge

The $1,646M revenue decline (-28.4%) can be decomposed:

The volume decline reflects almost entirely channel inventory reduction (not farmer demand destruction). Farmer usage of diamide insecticides did not fall 28% — distributors simply stopped ordering as they worked down their own inventory.

Margin Analysis

Gross Margin Compression (39.2% → 32.0%)

The 720bps gross margin decline over two years reflects:

1. Volume deleverage: Fixed manufacturing costs spread over lower volumes
2. Price erosion: Rynaxypyr pricing under pressure from generic alternatives
3. Mix shift: Lower-value destocked products (older chemistry) moved more; higher-margin diamide moved less
4. Input cost timing: Some raw material cost headwinds in 2022 fed through to 2023 COGS

FMC's gross margin at normalized volumes and pricing should recover toward 36–39% — the core chemistry is inherently high-gross-margin. Manufacturing is largely outsourced (FMC is an asset-light formulator/marketer), limiting fixed cost drag.

EBITDA Margin Compression (23.0% → 20.6%)

• SG&A as % of sales increased significantly (relatively fixed cost base vs. lower revenue)
• R&D maintained (~8% of sales) despite revenue decline — FMC protected the innovation pipeline
• EBITDA margin at normalized $5B+ revenue should recover to 24–27% per analyst consensus

Free Cash Flow — The Critical Problem

FMC's FCF deteriorated dramatically:

• FY2021: ~$550M
• FY2022: ~$450M (lower despite higher EBITDA — AR buildup from extended LatAm terms)
• FY2023: ~$100M (EBITDA collapsed + significant working capital build)

Why FCF lagged EBITDA so severely:

• Accounts receivable: Brazil distribution involves 90–180 day payment terms. As revenue declined, FMC collected prior-year AR but also built new AR on extended terms.
• Inventory: FMC had to work down its own inventory as orders collapsed
• The compounding: In the downturn, FMC shipped less (hurting AR collection) while still carrying production costs

Working capital normalization (AR collection + inventory reduction) is a primary source of cash generation in the recovery. FMC guided for $400–600M FCF improvement from working capital alone as the cycle normalizes.

Adjusted EPS Trend

The trajectory reflects the severity of the 2023 earnings collapse. At $5.78 peak EPS and ~$2.65 trough, FMC experienced the deepest EPS decline among major ag input companies in 2023. The recovery path back to prior peak EPS ($5.50–6.00) likely requires FY2026+ given Rynaxypyr headwinds.

Cost Structure Analysis

FMC's cost structure is approximately:

• COGS (excl. amortization): ~60–65% of revenue at trough, 58–62% at normal
  • Raw materials/technical ingredients: ~35–40% of sales
  • Tolling/contract manufacturing: ~10–15%
  • Logistics/freight: ~8–10%
• R&D: ~7–9% of sales ($320–360M/year); protected through cycle
• SG&A: ~12–15% of sales (somewhat fixed; deleverage in downturn)
• Amortization of intangibles: ~$200M/year (non-cash; large from DuPont acquisition)

Asset-light model: FMC owns limited manufacturing — it primarily sources active ingredients (technical concentrates) from third-party manufacturers (many in China and India), then formulates and packages in regional facilities. This limits capex (~$80–120M/year, ~2% of sales) but creates supply chain risk.

Key Financial Ratios (FY2023)

Balance Sheet Snapshot (YE 2023)

The goodwill/intangibles balance ($3.2B) primarily reflects the 2017 DuPont Crop Protection acquisition premium. As Rynaxypyr (a key acquired asset) faces generic pressure, there is a non-zero risk of impairment testing scrutiny, though FMC has not disclosed any impairment flags to date.

Forward-Looking Considerations

Revenue recovery scenario:

• Base case: Revenue recovers to ~$4.8–5.2B by FY2025 as destocking ends and new products ramp
• Bull case: $5.2–5.5B on faster Isoflex/Cyazypyr traction and favorable ag commodity pricing
• Bear case: ~$4.2–4.5B if Rynaxypyr erosion exceeds new product gains

Margin recovery scenario:

• Base case: EBITDA margin returns to ~23–25% on volume recovery and pricing stabilization
• At $5.0B revenue × 24% EBITDA margin = $1.2B EBITDA (close to prior peak)
• FCF recovery to $500–700M as working capital normalizes